Stocks
Intra-Cellular Therapies (ITCI) EV/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | -11.0 | -6.96 | -13.5 | -16.7 | -40.2 | -35.0 | ||
| Changes by years, y/y, % | +547% | -37% | +94% | +23% | +141% | +88.3% | |||
Intra-Cellular Therapies. EV/EBITDA
Intra-Cellular Therapies. EV/EBITDA, changes, %
Intra-Cellular Therapies (ITCI) EV/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EV/EBITDA | ? | -19.4 | -28.1 | -26.3 | -40.3 | -47.5 | -35.0 | |
| Changes by years, y/y, % | +20% | +92% | +109% | +139% | +145% | |||
| Changes by quarters, q/q, % | +15% | +45% | -7% | +53% | +18% | |||
